Phase I Clinical Study of E7389

Phase 1 Completed 15 enrolled Eisai Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to determine the dose limiting toxicity and maximum tolerated dose of E7389 in patients with solid tumors. The secondary objectives are to investigate the pharmacokinetics, safety, estimated recommended dose, and anti-tumor effects (in evaluable cases) of E7389 in patients with solid tumors.

Timeline

Start: 2006-06
Primary completion: 2008-01
Completion: 2008-02

Publications

Mukohara T, Nagai S, Mukai H, Namiki M, Minami H. Eribulin mesylate in patients with refractory cancers: a Phase I study. Invest New Drugs. 2012 Oct;30(5):1926-33. doi: 10.1007/s10637-011-9741-2. Epub 2011 Sep 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eribulin	Small molecule	0.7 mg/m2	Intravenous
Subject	Eribulin	Small molecule	1 mg/m2	Intravenous
Subject	Eribulin	Small molecule	1.4 mg/m2	Intravenous
Subject	Eribulin	Small molecule	2 mg/m2	Intravenous

Phase I Clinical Study of E7389

Summary

Timeline

Publications

Drugs

Indications